NanoCarrier Co., Ltd. (4571.T)
JPY 150.0
(-1.96%)
JPY 150.0
(-1.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 975.37 Million JPY | -30.61% |
| 2022 | 1.4 Billion JPY | -38.45% |
| 2021 | 2.28 Billion JPY | 44.75% |
| 2020 | 1.57 Billion JPY | -0.19% |
| 2019 | 1.58 Billion JPY | -28.77% |
| 2018 | 2.21 Billion JPY | -59.96% |
| 2017 | 5.54 Billion JPY | 93.13% |
| 2016 | 2.86 Billion JPY | 25.08% |
| 2015 | 2.29 Billion JPY | 45.94% |
| 2014 | 1.57 Billion JPY | 11.27% |
| 2013 | 1.41 Billion JPY | 125.11% |
| 2012 | 627.7 Million JPY | 13.13% |
| 2011 | 554.86 Million JPY | 0.31% |
| 2010 | 553.13 Million JPY | 2.51% |
| 2009 | 539.58 Million JPY | -15.45% |
| 2008 | 638.15 Million JPY | -1.36% |
| 2007 | 646.93 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 189 Million JPY | -5.97% |
| 2023 Q3 | 180.54 Million JPY | -24.4% |
| 2023 Q4 | 201 Million JPY | 11.33% |
| 2023 Q1 | 355.01 Million JPY | 78.49% |
| 2023 Q2 | 238.8 Million JPY | -32.73% |
| 2023 FY | 975.37 Million JPY | -30.61% |
| 2022 Q1 | 415.44 Million JPY | -32.02% |
| 2022 Q4 | 198.89 Million JPY | -54.48% |
| 2022 FY | 1.4 Billion JPY | -38.45% |
| 2022 Q2 | 354.33 Million JPY | -14.71% |
| 2022 Q3 | 436.91 Million JPY | 23.31% |
| 2021 Q3 | 529.29 Million JPY | -9.2% |
| 2021 Q4 | 611.1 Million JPY | 15.46% |
| 2021 Q2 | 582.89 Million JPY | 3.99% |
| 2021 Q1 | 560.53 Million JPY | 12.43% |
| 2021 FY | 2.28 Billion JPY | 44.75% |
| 2020 FY | 1.57 Billion JPY | -0.19% |
| 2020 Q2 | 347.54 Million JPY | 3.98% |
| 2020 Q3 | 397.39 Million JPY | 14.34% |
| 2020 Q4 | 498.58 Million JPY | 25.46% |
| 2020 Q1 | 334.25 Million JPY | 16.8% |
| 2019 Q1 | 624.98 Million JPY | 33.12% |
| 2019 Q4 | 286.18 Million JPY | -23.0% |
| 2019 FY | 1.58 Billion JPY | -28.77% |
| 2019 Q2 | 297.98 Million JPY | -52.32% |
| 2019 Q3 | 371.64 Million JPY | 24.72% |
| 2018 FY | 2.21 Billion JPY | -59.96% |
| 2018 Q4 | 469.48 Million JPY | -27.11% |
| 2018 Q3 | 644.11 Million JPY | 45.55% |
| 2018 Q1 | 663.02 Million JPY | -11.28% |
| 2018 Q2 | 442.54 Million JPY | -33.25% |
| 2017 Q3 | 2.66 Billion JPY | 215.71% |
| 2017 Q1 | 1.28 Billion JPY | 52.14% |
| 2017 FY | 5.54 Billion JPY | 93.13% |
| 2017 Q4 | 747.29 Million JPY | -71.98% |
| 2017 Q2 | 844.62 Million JPY | -34.23% |
| 2016 Q2 | 692.83 Million JPY | 8.56% |
| 2016 Q1 | 638.19 Million JPY | -19.21% |
| 2016 Q4 | 844.06 Million JPY | 21.49% |
| 2016 Q3 | 694.78 Million JPY | 0.28% |
| 2016 FY | 2.86 Billion JPY | 25.08% |
| 2015 Q3 | 578.25 Million JPY | 20.15% |
| 2015 Q1 | 444.99 Million JPY | 1.74% |
| 2015 Q4 | 789.9 Million JPY | 36.6% |
| 2015 Q2 | 481.25 Million JPY | 8.15% |
| 2015 FY | 2.29 Billion JPY | 45.94% |
| 2014 Q1 | 408.73 Million JPY | 16.09% |
| 2014 FY | 1.57 Billion JPY | 11.27% |
| 2014 Q4 | 437.38 Million JPY | 3.36% |
| 2014 Q3 | 423.16 Million JPY | 39.7% |
| 2014 Q2 | 302.91 Million JPY | -25.89% |
| 2013 FY | 1.41 Billion JPY | 125.11% |
| 2013 Q2 | 349.28 Million JPY | -6.9% |
| 2013 Q3 | 336.46 Million JPY | -3.67% |
| 2013 Q4 | 352.09 Million JPY | 4.64% |
| 2013 Q1 | 375.15 Million JPY | 93.79% |
| 2012 FY | 627.7 Million JPY | 13.13% |
| 2012 Q3 | 156.77 Million JPY | 22.18% |
| 2012 Q2 | 128.32 Million JPY | -13.89% |
| 2012 Q4 | 193.59 Million JPY | 23.48% |
| 2012 Q1 | 149.01 Million JPY | 14.72% |
| 2011 Q4 | 129.89 Million JPY | 0.79% |
| 2011 Q1 | 147.74 Million JPY | 7.89% |
| 2011 FY | 554.86 Million JPY | 0.31% |
| 2011 Q3 | 128.87 Million JPY | -13.13% |
| 2011 Q2 | 148.36 Million JPY | 0.42% |
| 2010 Q1 | 142.49 Million JPY | 19.65% |
| 2010 Q4 | 136.93 Million JPY | 5.9% |
| 2010 Q3 | 129.3 Million JPY | -10.45% |
| 2010 Q2 | 144.39 Million JPY | 1.33% |
| 2010 FY | 553.13 Million JPY | 2.51% |
| 2009 Q2 | 136.42 Million JPY | -9.77% |
| 2009 Q3 | 132.86 Million JPY | -2.62% |
| 2009 FY | 539.58 Million JPY | -15.45% |
| 2009 Q4 | 119.1 Million JPY | -10.36% |
| 2009 Q1 | 151.19 Million JPY | 28.61% |
| 2008 Q3 | 114.76 Million JPY | 0.0% |
| 2008 Q4 | 117.55 Million JPY | 2.43% |
| 2008 FY | 638.15 Million JPY | -1.36% |
| 2007 FY | 646.93 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 24.064% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -69.096% |
| GNI Group Ltd. | 9.32 Billion JPY | 89.537% |
| Linical Co., Ltd. | 2.7 Billion JPY | 63.944% |
| Trans Genic Inc. | 2.15 Billion JPY | 54.84% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 34.59% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 68.24% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 47.475% |
| AnGes, Inc. | 8.9 Billion JPY | 89.044% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -3.424% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 94.917% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -136.173% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 62.012% |
| CanBas Co., Ltd. | 278 Million JPY | -250.853% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 14.556% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 46.348% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 39.182% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 58.916% |
| PeptiDream Inc. | 9.68 Billion JPY | 89.931% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 50.251% |
| Ribomic Inc. | 1.1 Billion JPY | 11.786% |
| SanBio Company Limited | 4.53 Billion JPY | 78.511% |
| Healios K.K. | 3.48 Billion JPY | 72.028% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 15.533% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 26.909% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 30.503% |
| StemRIM | 2.07 Billion JPY | 53.017% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 50.325% |
| FunPep Company Limited | 313.82 Million JPY | -210.805% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -1.812% |
| Stella Pharma Corporation | 963.98 Million JPY | -1.181% |
| TMS Co., Ltd. | 943.25 Million JPY | -3.405% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 10.512% |
| Cuorips Inc. | 598.11 Million JPY | -63.073% |
| K Pharma,Inc. | 543.94 Million JPY | -79.315% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.92% |
| ReproCELL Incorporated | 1.51 Billion JPY | 35.577% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 17.62% |
| StemCell Institute Inc. | 1.16 Billion JPY | 16.07% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 35.927% |
| CellSeed Inc. | 804.93 Million JPY | -21.174% |